改造的DRV化合物的先进分子机制在准HIV-1蛋白酶突变和中断单体二分化时
Bolin Tang1, Song Luo1, Qihang Wang1
1School of Physics and Electronics, Shandogfng Normal University, Jinan, 250014, China. duanll@sdnu.edu.cn.
Physical chemistry chemical physics : PCCP
|January 23, 2024
概括
新的HIV-1蛋白酶抑制剂对抗抗药性突变具有强烈的疗效. GRL-142有效地抑制HIV蛋白酶单体和双体,为抗击病毒耐药性提供了一个有希望的策略.
科学领域:
- 生物化学 生物化学
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
背景情况:
- 艾滋病毒-1蛋白酶 (PR) 是抗逆转录病毒疗法的关键标.
- 由PR突变驱动的新兴耐药性严重挑战了艾滋病毒治疗的有效性.
- 像达鲁纳维尔 (DRV) 这样的现有抑制剂面临抗药性,需要新的治疗策略.
研究的目的:
- 研究DRV和修改后的抑制剂 (GRL-142) 对野生类型和突变的HIV-1蛋白酶的抑制作用.
- 为了比较抑制机制,包括对PR单体和双体的影响.
- 评估结合性自由能量和残留物对抑制的特定贡献.
主要方法:
- 用分子动力学模拟来研究抑制剂-蛋白酶相互作用.
- 分子力学/Poisson-Boltzmann表面积 (MM/PBSA) 计算评估了结合的自由能量.
- 氨酸扫描结合相互作用法量化个体残留能量贡献.
主要成果:
- 测试的抑制剂对PR突变表现出强大的抑制作用.
- GRL-142对PR单体和双体都表现出强烈的抑制作用.
- 抑制剂结合和PR突变改变了关键残留距离 (D25-I50),阻碍了蛋白酶二分化和耐药性.
结论:
- 新型抑制剂,特别是GRL-142在克服HIV-1抗药性方面显示出显著的前景.
- 了解单体和二元水平的抑制剂相互作用,可以指导设计更有效的HIV-1蛋白酶抑制剂.
- 这项研究有助于开发下一代针对抗性机制的HIV治疗方法.
相关概念视频
01:10Retrovirus Life Cycles
46.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.0K
00:36Viral Mutations
32.3K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.3K